iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Sun Pharma’s subsidiary gets Health Canada approval for WINLEVI

20 Jun 2023 , 11:44 AM

Sun Pharma Canada Inc., a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited, announced that WINLEVI (clascoterone cream 1%) has been approved by Health Canada.

WINLEVI has bagged Health Canada’s approval as the foremost and sole androgen receptor inhibitor for effectively treating acne vulgaris (acne) in individuals aged 12 and above. It is also the most recent formulation designed to address the hormonal aspect of acne for patients up to 40 years of age in Canada.

‘Due to hormonal triggers, acne is a common condition. Topical acne treatments for Canadians that target the hormonal cascade of acne have been lacking, creating a gap in available options for addressing the said aspect,’ said Dr. Jerry K.L. Tan, dermatology specialist and founder of The Healthy Image Centre in Windsor, Ontario. ‘I am delighted that acne patients will soon have a new treatment option.’

WINLEVI may inhibit the effects of androgen receptors in sebaceous gland cells (oil-producing glands in the skin) to help reduce sebum (oil) production and inflammatory cytokines,1, 6, and thus inhibits the androgen cascade.

‘Sun Pharma strives to provide innovative dermatology medicines for Canadians, which fill the gap in necessary treatment options,’ said Abhay Gandhi, Sun Pharma’s North America CEO.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Sun Pharma
  • Sun Pharma Approval
  • Sun Pharma news
  • Sun Pharma Updates
  • WINLEVI
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.